Baseline participant characteristics
| Overall | Controls | Overall IMIDs | RA | IBD | SpA | Other IMIDs | Psoriasis | |
| Number of participants (n) | 1909 | 1152 | 757 | 226 | 178 | 142 | 122 | 89 |
| Age mean (SD) | 45.4 (15.2) | 41.8 (13.5) | 50.9 (16.1) | 59.3 (13.8) | 40.6 (14.2) | 49.8 (13.8) | 52.2 (16.9) | 50.1 (15.2) |
| Male n (%) | 1080 (56.6) | 744 (64.6) | 336 (44.4) | 62 (27.4) | 86 (48.3) | 81 (57.0) | 52 (42.6) | 55 (61.8) |
| Female n (%) | 824 (43.2) | 406 (35.2) | 418 (55.2) | 163 (72.1) | 92 (51.7) | 61 (43.0) | 69 (56.6) | 33 (37.1) |
| csDMARDs n (%) | 328 (17.2) | ̶ | 217 (28.7) | 116 (51.3) | 7 (3.9) | 35 (24.6) | 47 (38.5) | 12 (13.5) |
| bDMARDs n (%) | 542 (28.4) | ̶ | 438 (57.9) | 86 (38.1) | 162 (91.0) | 96 (67.6) | 42 (34.4) | 52 (58.4) |
| tsDMARDs n (%) | 17 (0.9) | ̶ | 17 (2.2) | 14 (6.2) | 0 (0.0) | 1 (0.7) | 1 (0.8) | 1 (1.1) |
| Glucocorticoids n (%) | 141 (7.4) | ̶ | 141 (18.6) | 54 (23.9) | 23 (12.9) | 12 (8.5) | 48 (39.3) | 4 (4.5) |
Data are presented as mean with SD or absolute number (n) with proportion (%).
bDMARDs, biologic disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; IBD, inflammatory bowel disease; IMIDs, immune-mediated inflammatory diseases; RA, rheumatoid arthritis; SpA, spondyloarthritis; tsDMARDs, target synthetic disease-modifying anti-rheumatic drugs.